Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Derosa

Showing results (21-30 of 109) with videos related to

Pageof 11
Sort By:
Tumori|February 24, 2015
Small-bowel neuroendocrine tumor and retroperitoneal fibrosis: efficacy of octreotide and tamoxifenElisa Biasco, Andrea Antonuzzo, Luca Galli, et al.
Oncotarget|December 21, 2020
Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinomaAnnalisa Guida, Gwénaël Le Teuff, Carolina Alves, et al.
Cancer Treatment Reviews|March 25, 2017
The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamideMarzia Del Re, Stefano Fogli, Lisa Derosa, et al.
Bulletin Du Cancer|June 27, 2022
Therapeutic sequencing in the era of first-line immune checkpoint inhibitor combinations, a novel challenge in patients with metastatic clear-cell renal cell carcinomaRonan Flippot, Violaine Gorgeu, Marc Pujalte, et al.
Clinical Genitourinary Cancer|February 12, 2018
Drug Holiday in Metastatic Renal-Cell Carcinoma Patients Treated With Vascular Endothelial Growth Factor Receptor InhibitorsKriti Mittal, Lisa Derosa, Laurence Albiges, et al.
Clinical Genitourinary Cancer|July 23, 2020
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation StudyFrancesco Massari, Vincenzo Di Nunno, Annalisa Guida, et al.
Nature Medicine|April 11, 2025
Impact of the ONCOBIOME network in cancer microbiome researchLaurence Zitvogel, Lisa Derosa, Bertrand Routy, et al.
Cancer Immunology Research|August 28, 2020
The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung CancerTaiki Hakozaki, Corentin Richard, Arielle Elkrief, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 31, 2020
Physiologic colonic uptake of <sup>18</sup>F-FDG on PET/CT is associated with clinical response and gut microbiome composition in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitorsLena Cvetkovic, Claudine Régis, Corentin Richard, et al.
Oncoimmunology|July 4, 2025
Benzodiazepines interfere with the efficacy of pembrolizumab-based cancer immunotherapy. Results of a nationwide cohort study including over 50,000 participants with advanced lung cancerLéa Montégut, Adrien Rousseau, Cinzia Ungolo, et al.
Pageof 11

Showing results (21-30 of 109) with videos related to

Sort By:
Pageof 11
Tumori|February 24, 2015
Small-bowel neuroendocrine tumor and retroperitoneal fibrosis: efficacy of octreotide and tamoxifenElisa Biasco, Andrea Antonuzzo, Luca Galli, et al.
Oncotarget|December 21, 2020
Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinomaAnnalisa Guida, Gwénaël Le Teuff, Carolina Alves, et al.
Cancer Treatment Reviews|March 25, 2017
The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamideMarzia Del Re, Stefano Fogli, Lisa Derosa, et al.
Bulletin Du Cancer|June 27, 2022
Therapeutic sequencing in the era of first-line immune checkpoint inhibitor combinations, a novel challenge in patients with metastatic clear-cell renal cell carcinomaRonan Flippot, Violaine Gorgeu, Marc Pujalte, et al.
Clinical Genitourinary Cancer|February 12, 2018
Drug Holiday in Metastatic Renal-Cell Carcinoma Patients Treated With Vascular Endothelial Growth Factor Receptor InhibitorsKriti Mittal, Lisa Derosa, Laurence Albiges, et al.
Clinical Genitourinary Cancer|July 23, 2020
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation StudyFrancesco Massari, Vincenzo Di Nunno, Annalisa Guida, et al.
Nature Medicine|April 11, 2025
Impact of the ONCOBIOME network in cancer microbiome researchLaurence Zitvogel, Lisa Derosa, Bertrand Routy, et al.
Cancer Immunology Research|August 28, 2020
The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung CancerTaiki Hakozaki, Corentin Richard, Arielle Elkrief, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 31, 2020
Physiologic colonic uptake of <sup>18</sup>F-FDG on PET/CT is associated with clinical response and gut microbiome composition in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitorsLena Cvetkovic, Claudine Régis, Corentin Richard, et al.
Oncoimmunology|July 4, 2025
Benzodiazepines interfere with the efficacy of pembrolizumab-based cancer immunotherapy. Results of a nationwide cohort study including over 50,000 participants with advanced lung cancerLéa Montégut, Adrien Rousseau, Cinzia Ungolo, et al.
Pageof 11